PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation PARIS--(BUSINESS WIRE)--LimFlow SA, a ...

PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)--LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...

An update in the New England Journal of Medicine has shown that transcatheter arterialization of the deep veins (TADV) using the LimFlow System is a reliable and long-lasting therapy helping patients ...

PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)-- LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...

Positive results from Limflow SA’s PROMISE II U.S. pivotal trial show its Limflow system for transcatheter arterialization of deep veins (TADV) led to sustained amputation-free survival and wound ...

TADV is an emerging minimally invasive stent that reroutes blood through a healthier vein, bypassing the blocked leg artery and restoring blood to the foot. PROMISE III is a prospective, multicenter, ...

Patients with a severe form of peripheral artery disease had low amputation rates, improved wound healing, and better quality of life 6 months after a procedure to reroute blood flow using LimFlow ...

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ...

Breakthrough procedure reduces amputation risk for patients with Chronic Limb-Threatening Ischemia We're not only saving legs–we're enabling these patients to retain their independence, lessen the ...

New Therapeutic Option Has Potential to Reduce Rate of Major Limb Amputation in U.S. LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic ...